Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $2.8 million.

  • Myriad Genetics' Capital Expenditures fell 2000.0% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year decrease of 4291.34%. This contributed to the annual value of $19.0 million for FY2024, which is 6993.67% down from last year.
  • As of Q3 2025, Myriad Genetics' Capital Expenditures stood at $2.8 million, which was down 2000.0% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Capital Expenditures ranged from a high of $23.5 million in Q1 2023 and a low of $2.8 million during Q2 2025
  • Over the past 5 years, Myriad Genetics' median Capital Expenditures value was $6.3 million (recorded in 2022), while the average stood at $8.2 million.
  • In the last 5 years, Myriad Genetics' Capital Expenditures surged by 49000.0% in 2022 and then tumbled by 7234.04% in 2024.
  • Myriad Genetics' Capital Expenditures (Quarter) stood at $3.4 million in 2021, then soared by 329.41% to $14.6 million in 2022, then crashed by 31.51% to $10.0 million in 2023, then tumbled by 64.0% to $3.6 million in 2024, then decreased by 22.22% to $2.8 million in 2025.
  • Its Capital Expenditures stands at $2.8 million for Q3 2025, versus $2.8 million for Q2 2025 and $5.3 million for Q1 2025.